{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-005649","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2025-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.376693+00:00","generated_at":"2026-05-28T02:05:35.048297+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"UroGen Pharma furnishes January 2025 corporate presentation; no material new disclosures","bullets":["Presentation reiterates UGN-102 PDUFA target date of June 13, 2025 and planned ODAC meeting.","Highlights ongoing Phase 3 UTOPIA study for UGN-103 and planned Phase 3 for UGN-104.","No new financial data or material changes disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-005649","json":"https://secwatch.observer/filing/0001193125-25-005649.json","markdown":"https://secwatch.observer/filing/0001193125-25-005649.md","text":"https://secwatch.observer/filing/0001193125-25-005649.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312525005649/0001193125-25-005649-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312525005649/d903812d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:05:35.048297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}